Thank you, Mr. Blum, for being here and for your testimony.

Well, if the purpose in doing this is to lower the cost of the drug to the end user or the end payer, and you could get there the same way by just charging 6 percent less or giving a rebate to the physician who, I guess, keeps that, it…

I think in spite of the push by many of my colleagues on the other side of the aisle to push you into direct negotiations on Medicare Part D, I think what you said is that it has been very, very successful at keeping prices low because of…

It's interesting sitting up here and listening to testimony, and Dr. Rosenfeld and Dr. Adamis seem like very good folks who have a very strong disagreement, yet the testimony from both of you is very credible.

But in a perfect world, you could do that yourself, right? I mean, in the world we live in today, which is not perfect----

You know, there was a lot of debate about that during the discussions regarding health care reform.

I mean, again, you sounded pretty credible on the front end, but what you're telling me right now is not particularly credible.

It seems like that a competitive market and keeping things competitive, much as has been alluded to in earlier testimony regarding Medicare Part D, would actually drive towards that end anyway, would it not?

everything we need to do needs to move us towards much, much greater competition and innovation

I think, again, to restate what you're saying is Medicare Part D works really, really well as far as the competition goes in lowering prices for seniors, but there are some isolated cases where when only one type of drug is available, we…

I do not understand why... this one entity is one that should have absolutely no checks and balances.

I realize a scheme has been concocted on the debt ceiling that allows Democrats to go into this next election continuing to ensure that spending to many of their constituents is at levels that please them; therefore, allowing them to run…